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Abstract
Background: Pulmonary tuberculosis (TB) with detectable Mycobacterium tuberculosis in the sputum is a major
source of transmission. In resource limited TB endemic settings, cure is declared through sputum smear
examination for acid fast bacilli without performing culture. This may lead to erroneous treatment outcomes as
viable bacteria may be missed due to the low sensitivity of direct smear method. The aim of this study was to
investigate if sterilizing cure is achieved among the new pulmonary TB cases declared cured by sputum smear
conversion and to evaluate the impact of addition of ethambutol in the continuation phase in achieving it.
Methods: New sputum smear-positive pulmonary TB patients registered at a tertiary care hospital in Pakistan from
November 2013 to March 2014 were followed under standard Directly Observed Treatment Short Course strategy
for 6 months. Half of these patients received ethambutol in addition to isoniazid and rifampicin in the continuation
phase. Sputum specimens were examined on microscopy at 2 months and at the end of treatment. Sputa of
patients with negative direct smear examination at the end of treatment were cultured.
Results: Among 5746 TB suspects, 1595 were new sputum smear positive pulmonary TB cases, and 533 were registered
at our hospital. Among these, 504 converted sputum negative at 2months and 348 converted at the end of 6 months of
treatment and were declared cured. Sputa of 204/348 patients were cultured, and 12/204 (6%) were culture-positive.
Culture positivity at 6months was not associated with bacterial load, smoking, diabetes, presence of cavities, history of
contact with TB patients, age, sex, socioeconomic status, or addition of ethambutol in the continuation phase.
Conclusion: Viable cultivable bacilli were detected in 6% of cured patients, which would have significant impact on the
control of TB. This highlights the need for an inexpensive and accurate surrogate marker for culture as it is not feasible to
perform culture in routine for monitoring treatment response in the low-resource settings. The treatment outcome did
not improve by addition of ethambutol emphasizing the need to find the optimal duration of treatment for individual or
carefully selected groups of patients.
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Background
Tuberculosis (TB) is a major global health concern. As
per World Health Organization (WHO) TB report in
2018, the annual global incidence has not decreased
below 10.0 million [1]. Pulmonary TB with detectable
Mycobacterium tuberculosis (MTB) in the sputum is a
major source of transmission, and therefore a focus of
global TB Control strategies. Sputum smear microscopy
for acid-fast bacilli (AFB) is a widely available, simple,
and inexpensive tool for pulmonary TB diagnosis and
treatment monitoring [2]. The standard treatment for
TB comprises an intensive phase with isoniazid (INH),
rifampicin, pyrazinamide, and ethambutol for 2 months,
followed by a continuation phase that comprises the
concomitant use of INH and rifampicin for another 4
months [3, 4]. This standard treatment period of 6
months was determined by acceptable rates of treatment
failure and disease recurrence after discontinuation of
chemotherapy and is considered effective for drug-
susceptible TB [5]. Response to TB treatment is moni-
tored by follow-up sputum smear microscopy at 2
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months and 5 months [4, 6]. Diminishing numbers of
AFB to smear-negative status during treatment is con-
sidered an indication of treatment success. According to
WHO a patient whose sputum smear or culture was
positive at the beginning of the treatment but who was
smear- or culture-negative in the last month of treatment
and on at least one previous occasion is declared cured at
the end of treatment [4]. In resource limited settings,
Mycobacterial culture is not routinely performed on spu-
tum smear-positive cases for monitoring treatment re-
sponse [4]. In the absence of culture a negative sputum
smear during the last months of treatment is considered
as cure. There is little information as to whether bacterial
sterilization is achieved after 6 months of treatment in all
cases [7] and whether sputum smear conversion is a satis-
factory method for measuring sterilizing cure.
A minimum two effective drugs is necessary in the
continuation phase of treatment to achieve successful
treatment outcome and to prevent the emergence of
multidrug resistant strains. A drug resistance survey in
Pakistan in 2016 has shown 7% INH resistance among
rifampicin sensitive cases [8]. This implies that about 7%
of the pulmonary TB cases would be receiving only one
effective drug in the continuation phase. This could con-
tribute towards failure to achieve the sterilization and
persistence of a small number of bacilli even after treat-
ment and emergence of resistant strains. According to
WHO, ethambutol can be added in continuation phase
of patients with known or suspected high levels of INH
resistance, but more evidence is needed to support this
recommendation [4]. The aim of this study was to inves-
tigate if sterilizing cure is achieved among the new pul-
monary TB cases declared cured by sputum smear
conversion and the impact of addition of ethambutol in
the continuation phase in achieving sterilizing cure.
Methods
Study setting and design
The study was conducted at Gulab Devi hospital (GDH),
from November 2013 to March 2014. GDH is a private,
not-for-profit, large, tertiary care hospital located in La-
hore, the capital city of the country’s largest province.
GDH is known for specialized TB care and presumptive
and diagnosed TB patients are referred from various dis-
tricts to GDH for consultation and /or treatment. Many
patients after the diagnosis are referred back to TB
clinics close to their residence for treatment.
This study was nested in another project to study recur-
rence rate of TB by addition of a third drug (ethambutol)
and prolongation of continuation phase to 6months (sub-
mitted for publication). New, sputum smear-positive, pul-
monary TB patients, without a history of previous TB
treatment, were included only if they had successful spu-
tum smear conversion at the end of treatment and also if
the culture was performed. All these patients were given
standard anti-TB treatment as per WHO guidelines [4].
Rifampicin, INH, ethambutol and pyrazinamide were
given for the initial 2 months (Intensive phase). After 2
months, patients were split into two groups. One group
was given rifampicin and INH for 4 months (continuation
phase), while for the other group, ethambutol was added
during the continuation phase along with INH and rifam-
picin. Follow up smears were done at the second, fifth and
sixth months of treatment. If sputum smear was found
positive at the end of second month, examination was re-
peated at third month of treatment as well. Patients who
were having negative sputum smear at the end of treat-
ment were declared cured. These patients were enrolled
in the study only if their sputa were sent for culture.
If the sputum smear of a patient was found to be posi-
tive at the fifth or sixth month of treatment, the case
was declared as treatment failure, excluded from the
study and referred to the laboratory for Xpert MTB/RIF
assay.. In cases where MTB deoxyribonucleic acid was
detected and rifampicin resistance was not shown, cat-
egory 2 treatment was started according to the WHO
guidelines [4]. Patients with rifampicin resistance were
referred to the Programmatic Management of Drug-
Resistant Tuberculosis site at GDH for further treatment
and management.
Clinical and laboratory investigations
Detailed clinical history of the patients was taken, includ-
ing history of smoking and diabetes. Physical examination
was performed. Baseline blood tests, human immunodefi-
ciency virus (HIV) screening and chest X-ray were done
for patients on their first visit. Two (spot and early morn-
ing) sputum specimens were taken and examined for the
presence of AFB by Ziehl-Neelsen staining method and
direct microscopic examination [9]. All investigations
were done at GDH laboratory which is a quality assured
laboratory participating in the external quality assurance
system provided by the provincial and national reference
laboratories of Pakistan. Two sputum samples were exam-
ined at the time of diagnosis, while a single sputum was
examined at each follow-up visit and at the end of treat-
ment. The definition of a new sputum smear-positive pul-
monary TB case was based on the presence of at least one
acid-fast bacillus in the sputum specimen. The microscopy
results were graded as per the guidelines of the Inter-
national Union Against Tuberculosis and Lung Disease
[10]. Sputa from the smear-negative cases at the end of
treatment were processed for cultures on Lowenstein-
Jensen (LJ) medium. Sputa were decontaminated and con-
centrated and the deposit was inoculated on two slopes of
LJ medium [9]. The reading of culture slopes was done
weekly. LJ culture tubes were kept for a maximum of 8
weeks at 37 °C before declaring them negative. Positive
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cultures were reported as soon as growth was detected.
Identification was based on the phenotypic appearance of
colonies and acid-fastness on Ziehl-Neelsen stained
smears. Confirmation of M. tuberculosis complex was
done by inhibition of its growth in a medium containing
0.5 mg/ml of para- nitrobenzoic acid [11]. In case of con-
tamination in inoculated tubes, or growth of AFB mixed
with contaminants, specimen /culture was reprocessed
using N-acetyl-L-cysteine-sodium hydroxide method at a
final concentration of 2% sodium hydroxide [9].
Statistical analysis
The data was entered into SPSS version 20 and cleaned
for further analysis. Binary logistic regression analysis was
carried out to identify factors associated with achieving
sterilizing cure. A Fisher’s Exact test was done to show the
difference between the proportions in each treatment
group. P-value of less than 0.05 was considered statistically
significant.
Results
Patient characteristics
A total of 5746 patients were identified as presumptive
TB cases from November 2013 to March 2014 (Fig. 1).
Among these 1738 (30%) were smear-positive for AFB,
and 1595 (92%) were new TB patients who were never
treated for TB before, or had taken anti-TB drugs for
less than 1 month. Among these 533 (34%) were regis-
tered at GDH. After 6 months of treatment, 348 (65%)
patients were declared cured by sputum smear micros-
copy. Culture was performed on 204 of these patients.
The demographic and clinical data of these 204 patients
with available culture results is shown in Table 1. Rela-
tively few (6.8%) patients were smokers with a male
predominance. The prevalence of diabetes mellitus was
low (5.4%), and none of these patients were positive for
HIV. Majority of the chest radiographs showed non-
cavitary pulmonary infiltrates (93.1%), and cavities were
seen in only 6.9% of cases. More than half of the pa-
tients belonged to low-income groups. History of TB
contact from a household member was reported by 39%
of the patients.
Treatment outcomes
After 2months of treatment, sputa from 201/204 (98.5%)
patients converted negative. At the end of 6months of
treatment, sputa from all the patients had converted nega-
tive. However, 12 of these sputum smear-negative cases
had viable bacteria recovered on their culture. Culture
positivity at 6 months was not associated with bacterial
load, smoking, diabetes, presence of cavities, history of
contact with TB case, age, sex, socioeconomic status, or
the additional drug in the continuation phase (Table 2).
Fig. 1 Flow chart of study design. GDH = Gulab Devi hospital, TB = Tuberculosis
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Treatment outcomes with additional drug in the
continuation phase
Characteristics of patients receiving different drug regimens
in the continuation phase were not different statistically
(Table 3). Patients who were given additional ethambutol
in the continuation phase had similar bacillary load and
radiographic findings at the start of treatment as those
who received the standard two drugs. The addition of
ethambutol did not seem to have an impact on sputum
sterilization at the end of treatment (p > 0.05).
Discussion
Standard 6 months of rifampicin containing treatment is
considered curative for new drug-sensitive pulmonary
TB, and the sputum smear conversion is considered as a
reliable marker for successful treatment. In this study,
we show that sterilizing cure was not achieved in all the
cured patients after standard treatment, and viable cul-
tivable bacilli were detected in 6% of patients despite
successful sputum smear conversion. Earlier studies have
shown that MTB may persist in lung tissue for months
to years even after bacterial sterilization is achieved at the
end of treatment [12–15]. A study has shown the presence
of MTB mRNA in the context of non-resolving and intensi-
fying lesions on positron emission tomography-computed
tomography (PET–CT) images after treatment completion
and bacterial sterilization suggesting that even apparently
sterilizing curative treatment for TB may not eradicate all
the MTB bacteria in most of the patients [7]. The persisting
bacilli could lead to relapse as shown in a study from
Uganda where 10% of successfully treated patients with
standard 6months regimen patients got recurrence of TB
within 1 year, and 81% of these recurrent TB cases were
due to relapse [16]. The relapse rates range from 2.6 to
9.7% after successful standard treatment and sterilization
cure [13, 16–18]. Based on these findings it can be specu-
lated that the relapse rate after non-sterilizing cure might
be even higher, which would have a significant impact on
the global control of TB. A study from Japan reported
complete resolution of all active pulmonary TB lesions on
PET-CT scan after 12months of treatment, and no relapse
at 1 year of follow-up [19]. These findings raise questions
on the presence of viable bacilli after treatment and
whether relapse is related to the duration of treatment. The
higher relapse rates in patient groups with impaired im-
munity support the concept that a competent immune re-
sponse has an important complementary role in the
ultimate control of residual bacteria after completion of
antibiotic treatment [18, 20, 21]. The findings of our study
highlights the need for improvement in monitoring treat-
ment response by developing a sensitive, specific and inex-
pensive surrogate marker for quantifying TB other than the
gold standard of culture, as it is not feasible to perform cul-
ture in routine for monitoring treatment response in the
low-resource high TB endemic setting.
Previous studies have shown that presence of the lung
cavities on chest X-ray at the start of treatment is in-
versely proportional to sterilization at the end of treat-
ment [22]. However, in our study, no association was
seen with cavities at the start of treatment and sputum
sterilization at 6 months of treatment. Culture positivity
of sputum at 2 months is thought to be associated with
culture positivity at 6 months implying high bacterial
load at the start of treatment could lead to unfavorable
outcomes [23]. We did not apply culture at 2 months
but higher bacillary load at the start of treatment, or
smear positivity at 2 months was not associated with cul-
ture positivity at the end of treatment. Lack of these
associations could be due to a small number of patients
with unfavorable outcome in our study.
In this study 5/12 culture-positive cases had a recent
history of TB in their family, implying the possibility of
reinfection from the home environment rather than
treatment failure as the source of culture positivity. Dif-
ferent studies in the past have shown that exogenous
Table 1 Demographic and clinical characteristics of sputum
smear-positive pulmonary TB patients
Age in years, median, (range) 25 (16–76)
Sex n (%)
Male 94 (46)
Female 110 (54)
History of contact with TB, n/N (%)
a Recent 41/204 (20.0)
b Previous 39/204 (19.2)
No history of contact 124/204 (60.8)
Prevalence of diabetes n/N (%) 11/204 (5.4)
Males 5/94 (5.3)
Females 6/110 (5.5)
Prevalence of HIV 0/204 (0)
Smokers n/N (%) 14/204 (6.8)
Males, n/N (%) 13/94 (13.8)
Females, n/N (%) 1/110 (0.9)
Chest X-ray
Cavitary lesion, n/N (%) 7/102 (6.9)
Non-cavitary infiltrates, n/N (%) 95/102 (93.1)
Not available 102/204 (50.0)
Income Group (PKR/month)
Low (0–15,000) n (%) 109 (53.4)
Middle (15,000 - 30,000) n (%) 9 (4.5)
Unknown n (%) 86 (42.1)
n number, N Total number, % percentage
aHistory of contact with active TB case during the course of diagnosis
and treatment
bHistory of contact with active TB case before diagnosis and treatment
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reinfection could be a major cause of recurrent TB after
achieving cure especially in TB endemic areas [24]. Pa-
tients who have had TB once are at an increased risk of
developing TB when re-infected. Relapse is shown to
occur early after treatment completion, whereas reinfec-
tion dominates after 1 year and shown to account for at
least half of recurrent disease [25]. These findings
emphasize the importance of achieving sterilizing cures
and preventing transmission.
In our cohort, the proportion (5%) of diabetics among
the TB patients was much lower than the prevalence of
diabetes mellitus in the general population in Pakistan,
which is shown to be 26.3% [26]. Additionally the lack of
association of diabetes with culture positivity at the end
of treatment does not confirm the earlier studies indicat-
ing diabetes as a risk factor for active pulmonary TB and
unfavorable treatment outcomes [20, 27, 28]. The preva-
lence of diabetes in our study could have been underesti-
mated as prevlance was based on patient history and
serum glucose levels were not measured, leaving the
possibility that some patients might have undiagnosed
diabetes. A cross-sectional study from Lahore, Pakistan
found 14.8% diabetics among TB patients by measuring
serum glucose and HbA1C levels [29]. This prevalence is
Table 2 Factors associated with positive sputum culture after 6 months of anti-TB treatment
Sputum status at the end of anti-TB treatment aP-value
Smear negative n/N (%) Culture negative
n/N (%)
Culture positive
n/N (%)
Age, years
16–35 144/144 (100) 136/144 (94.4) 8/144 (5.6) .708
36–55 44/44 (100) 40/44 ((90.9) 4/44 (9.1) .999
56–76 16/16 (100) 16/16 (100) 0/16 (0) .998
Male 94/94 (100) 88/94 (93.6) 6/94 (6.3) .585
Female 109/109 (100) 103/109 (93.5) 6/109 (5.5)
Smoker 14/204 (6.8) 14/14 (100) 0/14 (0) .999
Diabetes 11/204 (5.3) 11/11 (100) 0/11 (0) .999
bBacillary load before treatment
Scanty 20/204 (9.8) 18/20 (90.0) 2/20 (10.0) .661
+ 1 117/204 (57.4) 109/117 (93.2) 8/117 (6.8) .382
+ 2 37/204 (18.1) 36/37 (97.3) 1/37 (2.7) .661
+ 3 30/204 (14.7) 29/30 (96.7) 1/30 (3.3) .815
Smear positivity at 2 M 3/204 (1.5) 3/3 (100) 0/3 (0) 1.00
Chest X-ray
Cavitary lesions 7/102 (6.9) 6/7 (85.7) 1/7 (14.3) .265
Non-cavitary infiltrates 95/102 (93.1) 91/95 (95.8) 4/95 (4.2)
History of contact
cRecent 41/204 (20.0) 36/41 (87.8) 5/41 (12.2) .08
dPrevious 39/204 (19.2) 39/39 (100) 0/39 (100) .998
No history of contact 124/204 (60.8) 119/124 (95.9) 5/124 (4.1) .897
Income
Low 109/204 (53.4) 102/109 (93.6) 7/109 (6.4) .985
Middle 9/204 (4.5) 9/9 (100) 0/9 (0) .862
Unknown 86/204 (42.1) 81/86 (94.2) 5/86 (5.8) .999
Medicines in the continuation Phase
INH + Rifampicin 103/204 4/103 (3.9) 99/103 (96.1) .177
INH+ Rifampicin +Ethambutol 101/204 8/101 (7.9) 93/101 (92.1)
n number, N Total number, % percentage
aDifference between culture positive and culture negative groups
bGraded as per the guidelines of the International Union Against Tuberculosis and Lung Disease
cHistory of contact with active TB case during the course of diagnosis and treatment
dHistory of contact with active TB case before diagnosis and treatment
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higher than our cohort but still lower than the prevalence
in the general population. A Malaysian study reviewed
1267 active TB patients at a tertiary hospital and did not
find diabetes as a risk factor for treatment failure [30].
Thus diabetes may not be a substantial risk factor for all
pulmonary TB and unfavorable treatment responses.
Inadequate chemotherapy causing exposure of bacilli
to a single effective drug can lead to selection of resist-
ant subpopulations, and unfavorable treatment outcomes
[31–33]. The national prevalence of 7% INH resistance
among rifampicin sensitive cases in Pakistan implies that
a substantial number of TB patients receive only one ef-
fective drug in the continuation phase [8]. However, in
our study, addition of ethambutol in the continuation
phase did not affect sterilization of sputum. Ethambutol
is a bacteriostatic drug while INH is bactericidal. Despite
WHO recommendation, the evidence to quantify the
ability of ethambutol to achieve better outcomes when
used in combination to “protect rifampicin” in patients
with pretreatment INH resistance, is insufficient, and
further research is needed.
There are some shortcomings in the study. It is a rela-
tively small study, with a small number of unfavorable
outcomes. Culture was not performed in all smear-
negative cases due to resource constrains. Chest X-ray
results could not be retrieved for several patients, and
data on the recurrence of TB was not available. This
could have added bias in the study. Despite these short-
comings, the study provides useful information about
the treatment outcomes in the routine TB control pro-
gram settings and could contribute towards evidence for
improving routine TB care.
Conclusions
This study shows that 6% of the pulmonary TB cases
which were declared cured on sputum-smear conversion
at 6 months did not achieve sterilizing cure and were
not truly cured. These findings, extrapolated globally,
would have significant impact on the control of TB. This
emphasizes the need for an inexpensive and accurate
surrogate marker for culture as it is not feasible to per-
form culture in routine for monitoring treatment re-
sponse in the low-resource high TB endemic setting.
Addition of ethambutol in the continuation phase did
not result in a better sterilizing cure emphasizing the
need for more studies to find the optimal duration of
treatment, and adjusting TB treatment for individual or
carefully selected groups of patients.
Table 3 Characteristics of patients receiving different drug regimens in the continuation phase
INH + Rifampicin INH + Rifampicin + ethambutol
Age in years, median, (range) 25 (16–75) 25 (16–76)
Sex, n/N (%)
Male 46/103 (44.6) 48/101 (47.5)
Female 57/103 (55.3) 53/101 (52.4)
History of contact with TB, n/N (%)
a Recent 21/103 (20.3) 20/101 (19.8)
b Previous 17/103 (16.5) 22/101 (21.7)
No history of contact 65/103 (63.1) 59/101 (58.4)
Prevalence of HIV 0/103 0/103
Smoker n/N (%) 4/103 (3.8) 10/101 (9.9)
Prevalence of diabetes n/N (%) 8/103 (7.7) 3/101 (2.9)
cBacillary load before treatment n/N (%)
scanty 10/103 (9.7) 10/101 (9.9)
+ 1 57/103 (55.4) 60/101 (59.4)
+ 2 25/103 (24.2) 12/101 (11.9)
+ 3 11/103 (10.7) 19/101 (18.8)
Chest X-ray n/N (%)
Cavitary lesions 3/7 (42.9) 4/7 (57.1)
Non-cavitary infiltrates 49/95 (51.6) 46/95 (48.4)
Not available 50/102 (49.1) 52/102 (50.9)
n number, N Total number, % percentage
aHistory of contact with active TB case during the course of diagnosis and treatment
bHistory of contact with active TB case before diagnosis and treatment
cGraded as per guidelines of the International Union Against Tuberculosis and Lung Disease
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